Issue in cardiovascular nursingDiagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases
Section snippets
Biosynthesis and Physiology of Brain Natriuretic Peptide
BNP is a 32-amino acid hormone that was named so because it was initially detected in porcine brain.7, 8 Subsequent studies found that BNP is constitutively released from ventricular myocyte as a preprohormone of 134 amino acids, which are cleaved into a pro-BNP hormone (108 amino acids). On being stimulated into secretion, it is further cleaved into a 76-amino acid N-terminal fragment (NT-proBNP) and a 32-amino acid hormone (BNP).9, 10 Elevated mechanical ventricular load and probably
Action
Numerous studies found that the biological actions of BNP affect kidney, vascular vessels, endocrine, and heart. The earliest finding of BNP biological action was the increase of glomerular filtration rate, renal plasma flow, urine flow rate, and inhibiting distal sodium reabsorption, causing natriuresis and diuresis.10, 17, 18 BNP can inhibit cardiac sympathetic nervous system activity by reducing norepinephrine level at a low dose, and the renin-angiotensin-aldosterone system by suppressing
Diagnosis of Acute Left-Sided Heart Failure
Cardiorespiratory dysfunction is usually manifested with severe dyspnea, but the relative contributions of the cardiac and respiratory components can vary enormously. Correct assessment of the cardiac contribution to dyspnea carries important implications for prognosis and management. Therefore, it is imperative to be able distinguish CHF efficiently from other diseases producing similar clinical sequelae.8, 40
A plasma BNP cutoff value of 100 pg/mL is a widely cited threshold with high
Brain Natriuretic Peptide in Cardiovascular Diseases Other Than Left-Sided Heart Failure
Plasma BNP has been reported to be of potential use in a number of other clinical settings antedating or associated with heart failure. Therefore, plasma BNP may perform better when used to screen for a wide array of cardiovascular disorders (Table I).8
BNP has a recognized role in the counteractive response to ischemia. In patients with chronic stable angina, the BNP level was correlated with the size of the ischemic area.62, 63 In patients with unstable angina, the BNP level was higher than
Brain Natriuretic Peptide in Prognosis and Management of Chronic Heart Failure
There is prognostic value of BNP and NT-proBNP. Patients with higher values on admission and/or discharge to hospital generally do worse. Those with marked reductions during treatment do better.37, 58, 89
Current research90 suggests that a BNP level greater than 480 pg/mL may predict higher 6-month mortality and rehospitalization rates for patients with CHF. An elevated BNP level 48 hours after myocardial infarction seems to be a strong predictor of death or the reoccurrence of heart failure
Brain Natriuretic Peptide in Sepsis
BNP elevation in patients with sepsis can be considerably high, even though a cardiac disorder is not obvious. A small retrospective analysis revealed that BNP levels in patients with sepsis and preserved systolic left ventricular function can be as high as that in patients admitted to the hospital with CHF because of severely impaired systolic left ventricular function. In this study, six of eight patients with sepsis (more of them with septic shock) presented a BNP level of greater than 1.000
Brain Natriuretic Peptide in Other Noncardiovascular Critical Diseases
Liver cirrhosis may be associated with mildly elevated BNP and NT-proBNP levels, probably as the result of cirrhotic cardiomyopathy.106, 107
Brain disorders or brain injury affect BNP levels in the critical care settings: Plasma NT-proBNP levels are elevated in acute stroke and predict poststroke mortality.108 Release of BNP from the brain,109 or more probably from the heart,110 in subarachnoid hemorrhage is associated with more brain edema,111 cerebral vasospasm,112 and poorer outcome,113 and
Brain Natriuretic Peptide in Various Populations
Despite diseases with high plasma BNP levels there are physiologic factors associated with increased values. These factors include increasing age, female sex, and impaired renal function (Table I).117, 118
The increase of BNP levels seen with advancing age is to be expected on the basis of a physiologic decline in cardiac function.119 Consistent with the increase associated with female gender, hormone replacement causes an elevation of BNP.120 Exercise has little effect on BNP,121 but BNP
Conclusions
The plasma BNP test can be used in high-risk populations, such as those presenting to the hospital with dyspnea. In the setting of acute dyspnea, a BNP level of less than 100 pg/mL makes the diagnosis of CHF unlikely, whereas BNP levels of greater than 400 pg/mL44, 129 or greater than 500 pg/mL11, 43 are associated with a high probability of CHF. The intermediate range (BNP, 100-400 pg/mL or 500 pg/mL) is a gray zone, in which several conditions including stable left ventricular dysfunction and
References (129)
- et al.
B-type natriuretic peptide in cardiovascular disease
Lancet
(2003) - et al.
Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
J Am Coll Cardiol
(2001) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure
J Am Coll Cardiol
(1992)- et al.
Effects of heart failure on baroreflex control of sympathetic neural activity
Am J Cardiol
(1992) - et al.
Sepsis-associated myocardial dysfunction. diagnostic and prognostic impact of cardiac troponins and natriuretic peptides
Chest
(2006) - et al.
Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients
Chest
(2005) - et al.
Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure
J Am Coll Cardiol
(2004) - et al.
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
J Am Coll Cardiol
(2002) - et al.
Biomarkers in acute cardiac disease. the present and the future
J Am Coll Cardiol
(2006) - et al.
A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study
J Card Fail
(2001)
Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
Am Heart J
Plasma brain natriuretic peptide in assessment of acute dyspnoea
Lancet
Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction
Results from the Breathing Not Properly Multinational StudyJ Am Coll Cardiol
Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease
Heart Lung Circ
Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis
J Am Coll Cardiol
Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath
J Am Coll Cardiol
Biochemical detection of left ventricular systolic dysfunction
Lancet
Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
Am Heart J
Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
J Am Coll Cardiol
Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism
Am Heart J
Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea
Chest
Overnight change in brain natriuretic peptide levels in children with sleep-disordered breathing
Chest
Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease
Lancet
Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide
Peptides
B-type natriuretic peptide: a new measurement to distinguish cardiac from pulmonary causes of acute dyspnea
J Emerg Nurs
B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure
J Am Coll Cardiol
Significance of predischarge BNP on one-year outcome in decompensated heart failure-comparative study with echo-Doppler indexes
J Card Fail
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
Lancet
Stroke and statistical update 2002
Essentials of the diagnosis of heart failure
Fam Physician
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases
Congest Heart Fail
B-type natriuretic peptide: issues for the intensivist and pulmonologist
Crit Care Med
Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis
Clin Sci
The role of brain natriuretic peptide in systolic heart failure
Dimens Crit Care Nurs
Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction
Circulation
Brain natriuretic peptide and optimal management of heart failure
J Zhejiang Univ Sci B
Novel markers for heart failure diagnosis and prognosis
Curr Opin Cardiol
BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure
Am J Physiol
Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart
Am J Physiol
Brain and other natriuretic peptides: molecular aspects
Eur J Heart Fail
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment
Clin Endocrinol (Oxf)
Deconvolution analysis of cardiac natriuretic peptides during acute volume overload
Hypertension
Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension
J Hypertens
Effect of BNP on renal hemodynamics tubular function and vasoactive hormones in humans
Am J Physiol
Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure
Circulation
Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts
Hypertension
Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression
J Clin Invest
Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide
Cardiovasc Res
Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man
J Hypertens
Cited by (23)
Determinants of markedly increased B-type natriuretic peptide in patients with ST-segment elevation myocardial infarction
2011, American Journal of Emergency MedicinePlasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype
2010, Blood Cells, Molecules, and DiseasesBiochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD
2011, ThoraxCitation Excerpt :Stolz et al previously found that raised BNP during COPD exacerbations predicted the need for intensive care, but levels of BNP observed in that study were lower than values typically found in patients with left ventricular failure.23 This is confirmed in our study in which elevated levels of NT-proBNP were generally much lower than levels found in left ventricular failure.24 Elevated troponins have been associated with adverse outcomes in retrospective studies of COPD exacerbations.12 25–27
Pleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma
2023, Clinics and PracticeCardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes
2022, Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes